Glaukos Corp. (GKOS)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
Research Workspace
Put GKOS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 47% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 62% growth a year, above the roughly 38% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskGKOS needs its glaucoma product growth to keep compounding to justify the price. Revenue grew 58% year over year in the latest quarter. The company also beat its earnings estimate by 491.7%. It trades at 21 times sales versus a 3 times peer median. The market is pricing in more growth than we forecast. A guidance cut would be a meaningful negative for the stock. Peer multiples imply a price about 54% below where it trades. Our read remains intact. This read is provisional.
Trailing returns as of 2026-11-04. GKOS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 13 analysts currently covering GKOS (as of Nov 2026).
Based on 10 Wall Street analysts offering 12-month price targets for GKOS in the last 4 months.
Continue this research
Compare GKOS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GKOS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put GKOS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Increase revenue guidance for 2026
Raises 2026 sales guidance and projects $1B revenue in 2027, materially strengthening growth outlook.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $246.70
The last 12 months of price, then the range of analyst 12-month targets from today’s $246.70.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.

Advances: Increase revenue guidance for 2026
Official earnings call is a material venue for updated guidance and progress against objectives.

Advances: Increase revenue guidance for 2026
Earnings beat and raised guidance advance the 2026 revenue-growth objective.

Threatens: Advance pipeline of novel dropless platform technologies
Reimbursement risks could hinder product pipeline advancement.

Increased price target indicates confidence in revenue growth.